培菲康联合常规治疗对新生儿巨细胞病毒性肝炎的作用  

The effect of Bifico combined with conventional treatment on neonatal cytomegalovirus hepatitis

作　　者：蒲方[1] 郝雅芹 PU Fang;HAO Ya-qin(Baoding Second Central Hospital,Baoding,Hebei 072750,China;不详)

机构地区：[1]保定市第二中心医院,河北072750

出　　处：《中国微生态学杂志》2021年第12期1456-1461,共6页Chinese Journal of Microecology

摘　　要：目的探讨培菲康联合常规治疗对新生儿巨细胞病毒(CMV)性肝炎患者肝功能、免疫功能及肠道菌群的影响。方法选择2018年10月至2020年1月我院新生儿CMV性肝炎患儿104例,随机分为研究组与对照组,各52例。对照组患儿采取常规治疗,研究组在对照组基础上加用培菲康。观察两组患儿临床疗效、治疗前后肝功能指标[总胆汁酸(TBA)、总胆红素(TBIL)、谷草转氨酶(AST)、谷丙转氨酶(ALT)]、CMV-免疫球蛋白M(IgM)及CMV-DNA转阴率、肠道菌群(乳杆菌、双歧杆菌、酵母样真菌、肠杆菌)、免疫功能指标[干扰素-γ(IFN-γ)、白介素-10(IL-10)]水平及不良反应。结果研究组患儿总有效率(94.23%)高于对照组(78.85%),差异有统计学意义(P<0.05)。治疗后6周和12周,研究组患儿TBA、TBIL、AST、ALT水平均低于对照组(均P<0.05);研究组CMV-IgM及CMV-DNA转阴率(78.85%、75.00%)均高于对照组(50.00%、44.23%),差异有统计学意义(均P<0.05)。治疗后6周和12周,研究组患儿肠道乳杆菌、双歧杆菌、肠杆菌数量均高于对照组,酵母样真菌数量低于对照组;同时研究组患儿血清IFN-γ水平高于对照组,IL-10水平低于对照组(均P<0.05)。研究组患儿不良反应发生率(17.31%)与对照组(13.46%)相比差异无统计学意义(P>0.05)。结论培菲康联合常规治疗能改善新生儿CMV性肝炎患儿肠道菌群分布,纠正其免疫紊乱状态,改善患儿肝功能,提高疗效,且安全可靠。Objective To observe the effect of Bifico combined with conventional treatment on liver function, immunologic function and intestinal flora in neonates with cytomegalovirus(CMV) hepatitis. Methods From October 2018 to January 2020, 104 cases of neonates with CMV hepatitis in our hospital were selected and divided into Observation group or control group randomly, 52 cases each. Both groups were given conventional treatment, while the observation group was additionally given Bifico. The clinical efficacy and liver function indexes [total bile acid(TBA), total bilirubin(TBIL), aspartate aminotransferase(AST), alanine aminotransferase(ALT)], conversion rates of CMV-immunoglobulin M(IgM) and CMV-DNA, intestinal flora(Lactobacillus, Bifidobacterium, yeast-like fungi, Enterobacteriaceae), immune function indexes [interferon-γ(IFN-γ), interleukin-10(IL-10)] and adverse reactions before and after treatment in the two groups were observed. Results The total efficiency rate in the observation group(94.23%) was higher than that in the control group(78.85%)(P<0.05). After 6 weeks and 12 weeks of treatment, the levels of TBA, TBIL, AST and ALT in the observation group were lower than those in the control group respectively(all P<0.05);the conversion rates of CMV-IgM and CMV-DNA in the observation group(78.85%, 75.00%) were higher than those in the control group(50.00%, 44.23%) respectively(all P<0.05). After 6 weeks and 12 weeks of treatment, the counts of intestinal Lactobacillus, Bifidobacterium and Enterobacteriaceae in the observation group were higher, and that of yeast-like fungi was lower than in the control group(all P<0.05);the IFN-γ level in the observation group was higher than that in the control group, and that of IL-10 was lower than that in the control group(all P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group(17.31%) and the control group(13.46%)(P>0.05). Conclusion Bifico combined with conventional treatment for neonatal CMV hepatitis can impro

关 键 词：培菲康 常规治疗 新生儿巨细胞病毒性肝炎 肠道菌群 免疫功能 安全性 

分 类 号：R725[医药卫生—儿科]